

12-14 . (1999)
 $> 30 / ^2$.

(), Biomerica () WOMAC.
 (0,1 /).

Microsoft Office 2000 (. 8318137 28.05.2008).

3 6 . ,
 (. 1). 3
 - 17 % 14,5 %, - 17,2 % 25 % 12,1 % 9,8 %,
 WOMAC 10,8 % 5,2 %, - 12,4 % 10,6 %, -
 15,2 % 11,9 %
 60 % 59,1 %
 22,6 % 26,6 % , - 27,6 %
 28,6 % WOMAC
 21,4 % 20,2 %, - 23 % 24,9 %, - 24,9 % 21,5 %

I-

		3	6
	<u>16,5±0,38</u> 16,4±0,47	<u>14,5±0,37*</u> 14,8±0,45*	<u>6,6±0,36**</u> 6,7±0,42**
	<u>5,3±0,12</u> 5,5±0,09	<u>4,4±0,12*</u> 4,7±0,14*	<u>4,1±0,11**</u> 4,2±0,12**
	<u>2,9±0,08</u> 2,8±0,09	<u>2,4±0,07*</u> 2,1±0,08*	<u>2,1±0,09**</u> 2,0±0,08**
	<u>58,4±1,23</u> 55,9±1,59	<u>52,1±1,52*</u> 53,0±1,55	<u>45,9±1,29**</u> 44,6±1,42**
	<u>58,2±0,97</u> 57,4±0,83	<u>51,0±0,95*</u> 51,3±1,12*	<u>44,8±1,10**</u> 43,1±1,03**
	<u>47,3±0,70</u> 49,4±1,41	<u>43,0±0,95*</u> 43,5±1,30*	<u>38,1±0,85**</u> 38,8±1,12**
1. -		(n=32).	
2. -		(n=31).	
3. *	(<0,05)		3
4. **	(<0,05)		6

(. 2),
 3 22,6 % (<0,001),
 (>0,05). (<0,01),
 23,6 % (<0,001)
 (<0,01). 28,6 % (<0,001),

WOMAC – 16,9 % (<0,001), – 17,1 % (<0,001), – 18,1 %
 (<0,001). WOMAC
 (<0,01) (<0,01). (>0,05).

2 –

		3	6
	16,4±0,50	12,7±0,51*	5,5±0,28**
	5,5±0,10	4,2±0,16*	3,4±0,12**
	2,8±0,12	2,0±0,09*	1,8±0,06**
	54,3±1,15	45,1±1,42*	31,7±1,21**
	56,1±1,09	46,5±1,03*	41,6±0,83**
	50,8±1,38	41,6±0,83	34,2±1,02**
1. *	(<0,05)		3
2. *	(<0,05)		3
3. **	(<0,05)		6
4. **	(<0,05)		6

66,5 % (<0,05). 38,2 % (<0,05). 35,7 % (<0,05).
 WOMAC 41,6 %, – 32,7 %. (<0,01) (<0,01). (<0,01).
 34 %, – 32,7 %. ((96,9±3,13) %), (90,3±5,4) % (90±5,57) %
 3 – ((87,5±5,94) %)
 ((87,1±6,12) %) ((, ,))
 ((50±9,28) %, <0,05)
 (81,3±7,01) %, – (67,7±8,85) %, – (16,7±6,92) %, (<0,001) (<0,001) .
 , WOMAC.
 [12,
 13].
 (-1 , -1 , -6, -) , ,

(7,2±0,43), (7,1±0,41) (7,3±0,37) / (4,6±0,11) /
 3 (6,1±0,32),
 (6,2±0,35) (5,5±0,29) / ,
 (<0,05). 6
 (5,5±0,30) / . (<0,05), (5,3±0,27)
 6-
 (2, , -) -k ,
 - , - , -1 - -1 ,
 , [14].

- 1.
- 2.
- 3.

SUMMARY

CLINICAL AND ANTIINFLAMMATORY EFFECTIVENESS OF CHONDROPROTECTORS IN OBESITY-OSTEOARTHRITIS PATIENTS

O.I. Opimakh

Medical Institute of Sumy State University, Sumy

This study surveyed clinical-and-functional symptoms of osteoarthritis and of the C-reactive protein level in differently treated obese patients. In all patients there was established a positive clinical dynamics, followed by decrease in pain syndrome while movement and stationary position, constrained motion, as well as decrease in

Lequesne index's functional changes, were accompanied by decrease in C-reactive protein content. The most effective clinical and anti-inflammatory treatment is reported to be an application of chondroprotectors combination, thus justifying the necessity of its prescription to obesity ill patients.

Key words: *osteoarthritis, obesity, clinical-and-functional symptoms, C-reactive protein, chondroprotectors.*

1. Grazio S. Obesity: risk factor and predictor of osteoarthritis / S. Grazio, D. Balen // *Lijec. Vjesn.* – 2009. – Vol. 131, 1–2. – P. 22–26.
2. Bierma-Zeinstra S. M. Risk factors and prognostic factors of hip and knee osteoarthritis / S.M. Bierma-Zeinstra, B.W. Koes // *Nat. Clin. Pract. Rheumatol.* – 2007. – Vol. 3, 2. – P. 78–85.
3. Magliano . Obesity and arthritis / M. Magliano // *Menopause Int.* – 2008. – Vol. 14. – P. 149–154.
4. The association of body mass index and osteoarthritis of the knee joint: an examination of genetic and environmental influences / N.J. Manek, D. Hart, T.D. Spector [et al.]// *Arthritis Rheum.* – 2003. – Vol. 48. – P. 1024–1029.
5. An analysis of 14 molecular markers for monitoring osteoarthritis. Relationship of the markers to clinical end-points / I.G. Otterness, E. Weiner, A.C. Swindell [et al.]// *Osteoarthritis Cartilage.* – 2001. – Vol. 9, 3. – P. 224–231.
6. Sonne-Holm S. Osteoarthritis and obesity / S. Sonne-Holm, S. Jacobsen // *Ugeskr Laeger.* – 2006. – Vol.168, 2. – P. 187–190.
7. Do metabolic factors add to the effect of overweight on hand osteoarthritis? The Rotterdam Study / S. Dahaghin, S. M. Bierma-Zeinstra, B. W. Koes [et al.]// *Ann. Rheum. Dis.* – 2007. – Vol. 66. – P. 916–920.
8. Haslam D.W. Obesity / D.W. Haslam, W.P. James // *Lancet.* – 2005. – Vol. 366. – P. 1197–1209.
9. Wisse B.E. An integrative view of obesity / B.E. Wisse, F. Kim, M.W. Schwartz // *Science.* – 2007. – Vol. 318, 5852. – P. 928–929.
10. Influence of obesity on the development of osteoarthritis of the hip: a systematic review / A.M. Lieveense, S.M.A. Bierma-Zeinstra, A.P. Verhagen [et al.] // *Rheumatology.* – 2002. –Vol. 41. – P.1155–1162.
11. Inflammatory markers and physical function among older adults with knee osteoarthritis / B.W. Penninx, H. Abbas, W. Ambrosius [et al.] // *J. Rheumatol.* – 2004. – Vol. 31, 10. – P. 2027–2031.
12. Increased serum C reactive protein may reflect events that precede radiographic progression in osteoarthritis of the knee / M. Sharif, L. Shepstone, C.J. Elson [et al.] // *Ann. Rheum. Dis.* – 2000. – Vol. 59, 1. – P. 71–74.
13. Pain and high sensitivity C reactive protein in patients with chronic low back pain and acute sciatic pain / T. Sturmer, E. Raum, M. Buchner [et al.]// *Ann. Rheum. Dis.* – 2005. – Vol. 64. – P. 921–925.
14. Verbruggen G. Chondroprotective drugs in degenerative joint diseases / G. Verbruggen // *Rheumatology (Oxford).* – 2006. – Vol. 45, 2. – P. 129–138.